Intracellular serine protease inhibitor SERPINB4 inhibits granzyme M-induced cell death. 2011

Pieter J A de Koning, and J Alain Kummer, and Stefanie A H de Poot, and Razi Quadir, and Roel Broekhuizen, and Anne F McGettrick, and Wayne J Higgins, and Bart Devreese, and D Margaret Worrall, and Niels Bovenschen
Department of Pathology, University Medical Center Utrecht, Utrecht, The Netherlands.

Granzyme-mediated cell death is the major pathway for cytotoxic lymphocytes to kill virus-infected and tumor cells. In humans, five different granzymes (i.e. GrA, GrB, GrH, GrK, and GrM) are known that all induce cell death. Expression of intracellular serine protease inhibitors (serpins) is one of the mechanisms by which tumor cells evade cytotoxic lymphocyte-mediated killing. Intracellular expression of SERPINB9 by tumor cells renders them resistant to GrB-induced apoptosis. In contrast to GrB, however, no physiological intracellular inhibitors are known for the other four human granzymes. In the present study, we show that SERPINB4 formed a typical serpin-protease SDS-stable complex with both recombinant and native human GrM. Mutation of the P2-P1-P1' triplet in the SERPINB4 reactive center loop completely abolished complex formation with GrM and N-terminal sequencing revealed that GrM cleaves SERPINB4 after P1-Leu. SERPINB4 inhibited GrM activity with a stoichiometry of inhibition of 1.6 and an apparent second order rate constant of 1.3×10(4) M(-1) s(-1). SERPINB4 abolished cleavage of the macromolecular GrM substrates α-tubulin and nucleophosmin. Overexpression of SERPINB4 in tumor cells inhibited recombinant GrM-induced as well as NK cell-mediated cell death and this inhibition depended on the reactive center loop of the serpin. As SERPINB4 is highly expressed by squamous cell carcinomas, our results may represent a novel mechanism by which these tumor cells evade cytotoxic lymphocyte-induced GrM-mediated cell death.

UI MeSH Term Description Entries
D007694 Killer Cells, Natural Bone marrow-derived lymphocytes that possess cytotoxic properties, classically directed against transformed and virus-infected cells. Unlike T CELLS; and B CELLS; NK CELLS are not antigen specific. The cytotoxicity of natural killer cells is determined by the collective signaling of an array of inhibitory and stimulatory CELL SURFACE RECEPTORS. A subset of T-LYMPHOCYTES referred to as NATURAL KILLER T CELLS shares some of the properties of this cell type. NK Cells,Natural Killer Cells,Cell, NK,Cell, Natural Killer,Cells, NK,Cells, Natural Killer,Killer Cell, Natural,NK Cell,Natural Killer Cell
D007700 Kinetics The rate dynamics in chemical or physical systems.
D009154 Mutation Any detectable and heritable change in the genetic material that causes a change in the GENOTYPE and which is transmitted to daughter cells and to succeeding generations. Mutations
D011485 Protein Binding The process in which substances, either endogenous or exogenous, bind to proteins, peptides, enzymes, protein precursors, or allied compounds. Specific protein-binding measures are often used as assays in diagnostic assessments. Plasma Protein Binding Capacity,Binding, Protein
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D003602 Cytotoxicity, Immunologic The phenomenon of target cell destruction by immunologically active effector cells. It may be brought about directly by sensitized T-lymphocytes or by lymphoid or myeloid "killer" cells, or it may be mediated by cytotoxic antibody, cytotoxic factor released by lymphoid cells, or complement. Tumoricidal Activity, Immunologic,Immunologic Cytotoxicity,Immunologic Tumoricidal Activities,Immunologic Tumoricidal Activity,Tumoricidal Activities, Immunologic
D006367 HeLa Cells The first continuously cultured human malignant CELL LINE, derived from the cervical carcinoma of Henrietta Lacks. These cells are used for, among other things, VIRUS CULTIVATION and PRECLINICAL DRUG EVALUATION assays. Cell, HeLa,Cells, HeLa,HeLa Cell
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000951 Antigens, Neoplasm Proteins, glycoprotein, or lipoprotein moieties on surfaces of tumor cells that are usually identified by monoclonal antibodies. Many of these are of either embryonic or viral origin. Neoplasm Antigens,Tumor Antigen,Tumor Antigens,Antigen, Tumor,Antigens, Tumor
D013379 Substrate Specificity A characteristic feature of enzyme activity in relation to the kind of substrate on which the enzyme or catalytic molecule reacts. Specificities, Substrate,Specificity, Substrate,Substrate Specificities

Related Publications

Pieter J A de Koning, and J Alain Kummer, and Stefanie A H de Poot, and Razi Quadir, and Roel Broekhuizen, and Anne F McGettrick, and Wayne J Higgins, and Bart Devreese, and D Margaret Worrall, and Niels Bovenschen
July 2004, FEBS letters,
Pieter J A de Koning, and J Alain Kummer, and Stefanie A H de Poot, and Razi Quadir, and Roel Broekhuizen, and Anne F McGettrick, and Wayne J Higgins, and Bart Devreese, and D Margaret Worrall, and Niels Bovenschen
August 2000, The Journal of biological chemistry,
Pieter J A de Koning, and J Alain Kummer, and Stefanie A H de Poot, and Razi Quadir, and Roel Broekhuizen, and Anne F McGettrick, and Wayne J Higgins, and Bart Devreese, and D Margaret Worrall, and Niels Bovenschen
December 1998, FEBS letters,
Pieter J A de Koning, and J Alain Kummer, and Stefanie A H de Poot, and Razi Quadir, and Roel Broekhuizen, and Anne F McGettrick, and Wayne J Higgins, and Bart Devreese, and D Margaret Worrall, and Niels Bovenschen
September 2004, Journal of immunology (Baltimore, Md. : 1950),
Pieter J A de Koning, and J Alain Kummer, and Stefanie A H de Poot, and Razi Quadir, and Roel Broekhuizen, and Anne F McGettrick, and Wayne J Higgins, and Bart Devreese, and D Margaret Worrall, and Niels Bovenschen
January 1995, Proceedings of the National Academy of Sciences of the United States of America,
Pieter J A de Koning, and J Alain Kummer, and Stefanie A H de Poot, and Razi Quadir, and Roel Broekhuizen, and Anne F McGettrick, and Wayne J Higgins, and Bart Devreese, and D Margaret Worrall, and Niels Bovenschen
December 2004, The Journal of biological chemistry,
Pieter J A de Koning, and J Alain Kummer, and Stefanie A H de Poot, and Razi Quadir, and Roel Broekhuizen, and Anne F McGettrick, and Wayne J Higgins, and Bart Devreese, and D Margaret Worrall, and Niels Bovenschen
August 2014, Transplantation,
Pieter J A de Koning, and J Alain Kummer, and Stefanie A H de Poot, and Razi Quadir, and Roel Broekhuizen, and Anne F McGettrick, and Wayne J Higgins, and Bart Devreese, and D Margaret Worrall, and Niels Bovenschen
May 2007, Cancer,
Pieter J A de Koning, and J Alain Kummer, and Stefanie A H de Poot, and Razi Quadir, and Roel Broekhuizen, and Anne F McGettrick, and Wayne J Higgins, and Bart Devreese, and D Margaret Worrall, and Niels Bovenschen
January 2004, Acta haematologica,
Pieter J A de Koning, and J Alain Kummer, and Stefanie A H de Poot, and Razi Quadir, and Roel Broekhuizen, and Anne F McGettrick, and Wayne J Higgins, and Bart Devreese, and D Margaret Worrall, and Niels Bovenschen
April 2003, Blood,
Copied contents to your clipboard!